PAREXEL Launches Patient Innovation Center
PAREXEL's Patient Innovation Center is launched to help sponsors navigate patient centricity from protocol, through study implementation and commercialization access.
PAREXEL announced the launch of its Patient Innovation Center, designed to help guide sponsors in their efforts to improve efficiency and success across all areas of biopharmaceutical development including clinical trial design, recruitment, execution and market access. With a patient-centric approach, the Center can help sponsors improve the drug development process by reducing the practical, financial and geographical barriers patients and caregivers often face, and optimize patient involvement and engagement.
PAREXEL’s Patient Innovation Center services include clinical study planning, which incorporates the company's Patient-Centric Protocol Optimization service; study implementation, which includes elements such as online recruitment, eConsent, home nursing, direct-to-patient drug shipments, patient apps and video dosing to enhance patient experience and compliance and PAREXEL’s Patient Sensor Soluition service is focused on continuous data collection through the use of wearables; and Patient and Market Access.
Read the press release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
